Treating Contact Lens Discomfort With Varenicline Solution Nasal Spray 0.03mg

Part of paid clinical trials in Houston, Texas.

Sponsor
Ocular Aesthetics, LLC dba Ocular Clinical Trials
Study ID
NCT07705893
Status
Recruiting
Apply to this trial

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - 99 Years
Healthy Volunteers
Accepted

Interventions

  • Tyrvaya — DRUG
    Tyrvaya (varenicline solution 0.03 mg) is a nasal spray, which is dosed twice daily, that is indicated for treating signs and symptoms of dry eye disease (DED )This dropless ocular surface sparing dosing pattern is ideal for the busy CL patient because they can easily administer Tyrvaya twice a day while keeping their contact lens on.

Study Details

The objective of this study is to evaluate whether twice-daily use of Tyrvaya improves contact lens comfort in contact lens wearers.

Key Dates

First listed
Jul 15, 2026
Start date
Jul 28, 2026
Status verified
Jul 2026
Primary completion
Dec 31, 2026
Completion
Mar 31, 2027

Study Design

Enrollment
50 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Tyrvaya
    Participants will be given Tryvaya (Varenicline Solution Nasal Spray 0.03 mg) and instructed to use it twice daily while wearing their contact lenses to determine if the spray relieves symptoms associated with dry eye disease, and thus increases contact lens comfort.

Primary Outcome Measure

Contact Lens Dry Eye Questionnaire-8 (CLDEQ-8) [ Time Frame: Baseline as compared to 12 weeks ]

Central Contacts

Locations (1)

FacilityCityStateZIPSite coordinators
Ocular Clinical TrialsHoustonTexas77027
Vanesa Flores, OD
[email protected]
(713) 838-2020

Find similar trials in Houston, TX

By research site
Ocular Clinical Trials· Houston, TX

Related Studies